Related to Oncodesign, Ipsen Seal Potentially $149M LRRK2 Inhibitor Parkinson Disease Deal

• Ipsen Drops Irosustat Monotherapy Program in Cancer but Will Evaluate Combination Therapy Options
  
• Envoy Awarded MJFF Grant to Develop Oral Drug for Parkinson Disease
  
• Studies Show SUMO Protects Alpha-Synuclein Against Fibril Formation and Neurotoxicity
  
• BioFocus Collaborates with Michael J. Fox Foundation on Parkinson Disease Diagnostic
  
• Impax and GSK Report Positive Data from Third Phase III Study with Parkinson Disease Drug
  
• Mutations in Stress Response Gene Identified in Parkinson Disease
  
• Investigators Get $8M to Set Up Parkinson’s Brain Bank
  
• MJFF Awards AFFiRiS $1.5M for Phase I Study with Peptide-Based Parkinson Disease Vaccine
  
• Merck Serono Hands Parkinson Disease Drug Safinamide Back to Newron
  
• Biotie Axes Agreement to Acquire Newron on Latter’s Loss of Partner for Parkinson Disease Drug
  
• Elan, Cambridge University Launch CNS Disease Drug Discovery Facility
  
• ProteoTech, GSK Come Together for Parkinson Drug R&D
  
• Amarantus Pays Power3 $0.5M for Biomarker IP to Diagnose Parkinson Disease
  
• iPSC-Derived Progenitors Differentiate into Dopaminergic Neurons in Primate Model of PD
  
• Navidea Gains Option to Alseres’ Parkinson Disease Imaging Agent
  
• To-BBB Wins MJFF Funding to Support Preclinical Brain-Targeting Parkinson Disease Drug
  
• Abbott’s Parkinson Therapy Benefits On and Off Times in Phase III Trial
  
• MJFF Sponsors Phase Ib Trial with Sanofi's Parkinson Disease Candidate
  
• AFFiRiS Initiates Trial with Alpha-Synuclein-Targeting Parkinson Disease Vaccine
  
• Newron to Buy NeuroNova for €15.4 in Shares for Clinical ALS and Parkinson Disease Drugs